A number of research firms have changed their ratings and price targets for Waters (NYSE: WAT):
- 5/7/2026 – Waters had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $350.00 price target on the stock.
- 5/7/2026 – Waters had its price target raised by Barclays PLC from $400.00 to $425.00. They now have an “overweight” rating on the stock.
- 5/6/2026 – Waters had its price target raised by UBS Group AG from $330.00 to $375.00. They now have a “neutral” rating on the stock.
- 5/6/2026 – Waters had its price target raised by TD Cowen from $345.00 to $385.00. They now have a “hold” rating on the stock.
- 5/6/2026 – Waters was given a new $387.00 price target by Robert W. Baird.
- 5/6/2026 – Waters had its price target raised by JPMorgan Chase & Co. from $330.00 to $345.00. They now have a “neutral” rating on the stock.
- 4/20/2026 – Waters had its “hold (c)” rating reaffirmed by Weiss Ratings.
- 4/13/2026 – Waters had its price target lowered by UBS Group AG from $370.00 to $330.00. They now have a “neutral” rating on the stock.
- 4/6/2026 – Waters was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $350.00 price target on the stock.
- 4/1/2026 – Waters was upgraded by The Goldman Sachs Group, Inc. to “strong-buy”.
- 3/25/2026 – Waters had its price target lowered by Deutsche Bank Aktiengesellschaft from $370.00 to $330.00. They now have a “hold” rating on the stock.
Insider Transactions at Waters
In other news, Director Wei Jiang bought 500 shares of Waters stock in a transaction dated Monday, March 16th. The shares were bought at an average price of $289.46 per share, for a total transaction of $144,730.00. Following the purchase, the director owned 3,441 shares of the company’s stock, valued at approximately $996,031.86. This trade represents a 17.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is owned by company insiders.
Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.
Featured Stories
- Five stocks we like better than Waters
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Waters Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
